Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodolfo Sacco

Showing results (81-90 of 169) with videos related to

Pageof 17
Sort By:
European Journal of Radiology|April 7, 2011
Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort studyIrene Bargellini, Rodolfo Sacco, Elena Bozzi, et al.
World Journal of Gastroenterology|April 17, 2009
Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: a cohort studyRodolfo Sacco, Marco Bertini, Pasquale Petruzzi, et al.
World Journal of Gastroenterology|June 16, 2015
Transarterial radioembolization for hepatocellular carcinoma: An update and perspectivesRodolfo Sacco, Valeria Mismas, Sara Marceglia, et al.
Journal of Vascular and Interventional Radiology : JVIR|August 19, 2011
Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinomaRodolfo Sacco, Irene Bargellini, Marco Bertini, et al.
Endocrine-Related Cancer|May 12, 2021
Target therapies plus somatostatin analogs in NETs: a network meta-analysisSara Pusceddu, Antonio Facciorusso, Luca Giacomelli, et al.
Internal and Emergency Medicine|March 29, 2024
Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenibBernardo Stefanini, Francesco Tovoli, Franco Trevisani, et al.
Transplantation|August 22, 2022
Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential TreatmentsFrancesco Tovoli, Dante Pio Pallotta, Vito Sansone, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|September 19, 2017
Bismuth-based quadruple therapy following H. pylori eradication failures: a multicenter study in clinical practiceAngelo Zullo, Vincenzo De Francesco, Annamaria Bellesia, et al.
Future Oncology (London, England)|February 19, 2013
Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter studyMauro Borzio, Fabio Fornari, Ilario De Sio, et al.
Journal of Cancer Research and Clinical Oncology|December 18, 2017
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuationFranco Trevisani, Giovanni Brandi, Francesca Garuti, et al.
Pageof 17

Showing results (81-90 of 169) with videos related to

Sort By:
Pageof 17
European Journal of Radiology|April 7, 2011
Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort studyIrene Bargellini, Rodolfo Sacco, Elena Bozzi, et al.
World Journal of Gastroenterology|April 17, 2009
Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: a cohort studyRodolfo Sacco, Marco Bertini, Pasquale Petruzzi, et al.
World Journal of Gastroenterology|June 16, 2015
Transarterial radioembolization for hepatocellular carcinoma: An update and perspectivesRodolfo Sacco, Valeria Mismas, Sara Marceglia, et al.
Journal of Vascular and Interventional Radiology : JVIR|August 19, 2011
Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinomaRodolfo Sacco, Irene Bargellini, Marco Bertini, et al.
Endocrine-Related Cancer|May 12, 2021
Target therapies plus somatostatin analogs in NETs: a network meta-analysisSara Pusceddu, Antonio Facciorusso, Luca Giacomelli, et al.
Internal and Emergency Medicine|March 29, 2024
Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenibBernardo Stefanini, Francesco Tovoli, Franco Trevisani, et al.
Transplantation|August 22, 2022
Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential TreatmentsFrancesco Tovoli, Dante Pio Pallotta, Vito Sansone, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|September 19, 2017
Bismuth-based quadruple therapy following H. pylori eradication failures: a multicenter study in clinical practiceAngelo Zullo, Vincenzo De Francesco, Annamaria Bellesia, et al.
Future Oncology (London, England)|February 19, 2013
Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter studyMauro Borzio, Fabio Fornari, Ilario De Sio, et al.
Journal of Cancer Research and Clinical Oncology|December 18, 2017
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuationFranco Trevisani, Giovanni Brandi, Francesca Garuti, et al.
Pageof 17